- Settlement amount: $39 million
- Parties: Sarepta, Regenxbio, Catalent, University of Pennsylvania
Sarepta Therapeutics agreed to pay $39 million to Regenxbio to resolve patent infringement litigation. The settlement covers Sarepta gene therapy products using the contested technology. No admission of wrongdoing. Sarepta had already accrued the charge.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.